Proteomic analysis of a NAP1 Clostridium difficile clinical isolate resistant to metronidazole.
BACKGROUND: Clostridium difficile is an anaerobic, Gram-positive bacterium that has been implicated as the leading cause of antibiotic-associated diarrhea. Metronidazole is currently the first-line treatment for mild to moderate C. difficile infections. Our laboratory isolated a strain of C. diffici...
Main Authors: | Patrick M Chong, Tarah Lynch, Stuart McCorrister, Pamela Kibsey, Mark Miller, Denise Gravel, Garrett R Westmacott, Michael R Mulvey, Canadian Nosocomial Infection Surveillance Program (CNISP) |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3882210?pdf=render |
Similar Items
-
Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2014–2018
by: Canadian Nosocomial Infection Surveillance Program
Published: (2020-05-01) -
First report of Clostridium difficile NAP1/027 in a Mexican hospital.
by: Adrián Camacho-Ortiz, et al.
Published: (2015-01-01) -
Reconsidering the sporulation characteristics of hypervirulent Clostridium difficile BI/NAP1/027.
by: David A Burns, et al.
Published: (2011-01-01) -
Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
by: George Tannous, et al.
Published: (2010-09-01) -
Prevalence of metronidazole-resistant clostridium difficile: a meta-analysis in Iran
by: Ghobad Moradi, et al.
Published: (2019-05-01)